drugset / Trial / NCT03346369
Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis
NaSingle-groupOpen-labelTreatment
Summary
This study investigates the efficacy and the safety of Lanthanum Carbonate for the reduction of urinary oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis.
Timeline
- Start
- 2017-08-18
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanthanum Carbonate | Other / unclassified | 250 mg | — |
| Subject | Lanthanum Carbonate | Other / unclassified | 500 mg | — |